Paper46338
Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease.
Miller GJ and 1 other. Lancet, 1975. Cited by 2,692 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Papers, record 46338. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/46338
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease.
- PubMed
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cholesterol | Major topic |
| Coronary Disease | Major topic |
| Lipoproteins, HDL | Major topic |
| Arteries | |
| Arteriosclerosis | |
| Denmark | |
| Female | |
| Finland | |
| Humans | |
| Inuit | |
| Lipoproteins, LDL | |
| Lipoproteins, VLDL | |
| Liver | |
| Male | |
| Middle Aged | |
| Sex Factors | |
| Sweden | |
| Triglycerides | |
| United States |
Source PubMed
Cited by388
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2,692 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,142,223 | Reframing the High-density Lipoprotein (HDL) Hypothesis in Light of Clinical Trials of Cholesterol Ester Transfer Protein (CETP) Inhibitors. | Drugs | 2026 | https://conductscience.org/library/papers/42142223 | PubMed |
| 41,750,567 | Antioxidant Role of High-Density Lipoprotein. | Antioxidants (Basel) | 2026 | https://conductscience.org/library/papers/41750567 | PubMed |
| 41,199,511 | Impact of Glucose Metabolism Status on the Association between Apolipoprotein A-I and Ischemic Risk in Patients with Coronary Artery Disease: A Large-Sample Cohort Study. | Endocrinol Metab (Seoul) | 2025 | https://conductscience.org/library/papers/41199511 | PubMed |
| 40,545,793 | Development and validation of direct assay for cholesterol content of erythrocytes. | Biosci Rep | 2025 | https://conductscience.org/library/papers/40545793 | PubMed |
| 40,298,833 | How Does HDL Participate in Atherogenesis? Antioxidant Activity Versus Role in Reverse Cholesterol Transport. | Antioxidants (Basel) | 2025 | https://conductscience.org/library/papers/40298833 | PubMed |
| 40,298,782 | HDL-Cholesterol and Triglycerides Dynamics: Essential Players in Metabolic Syndrome. | Antioxidants (Basel) | 2025 | https://conductscience.org/library/papers/40298782 | PubMed |
| 40,148,862 | Association between exposure to brominated flame retardants (BFRs) and blood lipid profiles in American adults: a cross-sectional study. | Lipids Health Dis | 2025 | https://conductscience.org/library/papers/40148862 | PubMed |
| 39,867,202 | Dynamics of HDL-Cholesterol Following a Post-Myocardial Infarction Cardiac Rehabilitation Program. | Rev Cardiovasc Med | 2025 | https://conductscience.org/library/papers/39867202 | PubMed |
| 39,834,741 | Bile acids and incretins as modulators of obesity-associated atherosclerosis. | Front Cardiovasc Med | 2024 | https://conductscience.org/library/papers/39834741 | PubMed |
| 39,752,447 | Ratio of remnant cholesterol to high-density lipoprotein cholesterol in relation to gestational diabetes mellitus risk in early pregnancy among Korean women. | PLoS One | 2025 | https://conductscience.org/library/papers/39752447 | PubMed |
| 39,728,045 | Up-to-Date Snapshot of Current and Emerging Medical Therapies in Primary Biliary Cholangitis. | J Pers Med | 2024 | https://conductscience.org/library/papers/39728045 | PubMed |
| 39,483,014 | Effects of dietary metabolizable energy and crude protein levels on laying performance, egg quality and fecal microbiota of Taihe Silky Fowl during the peak laying period. | Anim Biosci | 2025 | https://conductscience.org/library/papers/39483014 | PubMed |
| 39,076,640 | Lipid Profile and Atrial Fibrillation: Is There Any Link? | Rev Cardiovasc Med | 2022 | https://conductscience.org/library/papers/39076640 | PubMed |
| 38,994,965 | High-Density Lipoprotein Modifications: Causes and Functional Consequences in Type 2 Diabetes Mellitus. | Cells | 2024 | https://conductscience.org/library/papers/38994965 | PubMed |
| 38,033,552 | Lipids and lipoproteins may play a role in the neuropathology of Alzheimer's disease. | Front Neurosci | 2023 | https://conductscience.org/library/papers/38033552 | PubMed |
| 38,031,838 | Understanding HDL Metabolism and Biology Through In Vivo Tracer Kinetics. | Arterioscler Thromb Vasc Biol | 2024 | https://conductscience.org/library/papers/38031838 | PubMed |
| 37,325,194 | Mendelian randomization. | Nat Rev Methods Primers | 2022 | https://conductscience.org/library/papers/37325194 | PubMed |
| 37,297,860 | Advances in Cardiovascular Pharmacology in Atherosclerotic-Related Therapeutic Areas: Addressing Patients' Clinical Needs. | J Clin Med | 2023 | https://conductscience.org/library/papers/37297860 | PubMed |
| 36,474,148 | Evaluation of (sdLDLc*HCYc)/HDLc ratio in clinical auxiliary diagnosis of primary cerebral infarction. | BMC Cardiovasc Disord | 2022 | https://conductscience.org/library/papers/36474148 | PubMed |
| 36,364,251 | Plasma Metabolites and Liver Composition of Broilers in Response to Dietary Ulva lactuca with Ulvan Lyase or a Commercial Enzyme Mixture. | Molecules | 2022 | https://conductscience.org/library/papers/36364251 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/46338
GET https://conductscience.org/api/papers/v1/46338/cited_by?page=2